Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Limited has announced the cessation of over 4 million performance rights and nearly 28 million options due to unmet conditions as of June 26, 2024. This significant change in securities reflects conditions that were not or could not be satisfied, affecting the company’s issued capital structure.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
